Grant: Banting Postdoctoral Fellowship Program
University of Toronto
$140,000.00
Novel structural approaches towards a better understanding of HIV integrase, the architect of viral persistence in human cells
EF 2015-16
Résumé
For more than thirty years, the HIV/AIDS pandemic has been a major public health concern. Currently, over 35 million people are living with HIV and there are an estimated 2 million new infections every year and 1.5 million AIDS-related deaths. Highly active antiretroviral therapy (HAART) has significantly improved the overall health outcomes of those living with HIV/AIDS, transitioning HIV from an automatic death sentence to a chronic disease. However, current treatments do not cure individuals of HIV. The HIV integrase is responsible for the irreversible insertion of the viral DNA into human chromosomal DNA. It is therefore an important target for antiviral drugs as well as a protein that may be manipulated towards achieving a cure. Accordingly, drugs targeting integrase, raltegravir and elvitegravir, represent are highly potent, but the virus quickly evolves resistance substitutions. A new integrase drug, dolutegravir, is the most potent HIV drug to date and the virus does not easily evolve resistance. A proper understanding of the effect of this drug and other roles of integrase in HIV pathogenesis requires an atomic resolution crystal structure, however this is complicated by the low solubility of HIV integrase, which prevents structural studies of the full-length protein. The integrase protein from non-pathogenic prototype foamy virus is soluble and has been crystallized. In this project we propose the creation of integrase chimeras between HIV integrase and prototype foamy virus integrase. These chimeras would be tested for their impact on viral infectiousness and drug susceptibility, and will ultimately be crystallized in complex with viral and human DNA mimics. We aim to realize the first structures of HIV integrase bound to clinically relevant drugs and DNA. This project will yield a better understanding of HIV integrase and provide a master blueprint to understand drug resistance pathways and to design new classes of drugs for AIDS prevention/therapy.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
335281
Name
Quashie Peter K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Novel structural approaches towards a better understanding of HIV integrase, the architect of viral persistence in human cells
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Enzyme Mechanism; Hiv Integrase; Hiv/Aids; Integrase Inhibitors; Protein Crystallization; Protein Engineering; Structural Biology; Viral Pathogensis
Abstract
For more than thirty years, the HIV/AIDS pandemic has been a major public health concern. Currently, over 35 million people are living with HIV and there are an estimated 2 million new infections every year and 1.5 million AIDS-related deaths. Highly active antiretroviral therapy (HAART) has significantly improved the overall health outcomes of those living with HIV/AIDS, transitioning HIV from an automatic death sentence to a chronic disease. However, current treatments do not cure individuals of HIV. The HIV integrase is responsible for the irreversible insertion of the viral DNA into human chromosomal DNA. It is therefore an important target for antiviral drugs as well as a protein that may be manipulated towards achieving a cure. Accordingly, drugs targeting integrase, raltegravir and elvitegravir, represent are highly potent, but the virus quickly evolves resistance substitutions. A new integrase drug, dolutegravir, is the most potent HIV drug to date and the virus does not easily evolve resistance. A proper understanding of the effect of this drug and other roles of integrase in HIV pathogenesis requires an atomic resolution crystal structure, however this is complicated by the low solubility of HIV integrase, which prevents structural studies of the full-length protein. The integrase protein from non-pathogenic prototype foamy virus is soluble and has been crystallized. In this project we propose the creation of integrase chimeras between HIV integrase and prototype foamy virus integrase. These chimeras would be tested for their impact on viral infectiousness and drug susceptibility, and will ultimately be crystallized in complex with viral and human DNA mimics. We aim to realize the first structures of HIV integrase bound to clinically relevant drugs and DNA. This project will yield a better understanding of HIV integrase and provide a master blueprint to understand drug resistance pathways and to design new classes of drugs for AIDS prevention/therapy.
Competitiondate
201509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Quashie, Peter K
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~